Navigation Links
Landmark dental school study uses genetic test to help predict gum disease
Date:8/12/2010

ANN ARBOR, Mich.---University of Michigan School of Dentistry has signed an agreement with Interleukin Genetics Inc. to conduct what may be the largest clinical study to date using genetic testing to assess the risk for gum disease.

William Giannobile, professor at U-M dentistry and director of the Michigan Center for Oral Health Research at the School of Dentistry, will lead the study for U-M.

"It's an exciting study because it's a way to use genetic testing to personalize a dental treatment plan and the frequency of dental care visits of patients as it relates to oral care," said Giannobile. "It's a way to customize patient care."

"One of the goals of personalized health care is to detect disease earlier and prevent it more effectively," said Kenneth Kornman, president and chief scientific officer of Waltham, Mass. based-Interleukin. The study will use Interleukin's PST test as one part of a periodontitis risk assessment, said Kornman, who is also an alumnus of the U-M Dental School. Research has shown that genetics plays a large role in gum disease, and research also suggests that severe gum disease is a risk factor for other chronic disease complications such as heart disease or low birth weight.

U-M scientists will examine 15 years of patient clinical outcome data provided by a Michigan-based insurance company. Scientists will then recruit at least 4,000 of those patients and get their genetic information using the PST, Giannobile said.

They will combine this genetic information with two other common risk factors, smoking and diabetes, then measure tooth survival rates to see how those results lined up with the treatment plans people received over the 15 years. Some patients may have needed more dental visits, some may have required less, Giannobile said.

The PST genetic test works by identifying genetic variations that are predictive of severe gum disease and tooth loss in some patients. The test may be used on all ethnic populations and must only be given once in a lifetime to identify at-risk patients. Specifically, the test identifies genetic variants that regulate a protein that when overexpressed, is thought to be associated with destruction of soft tissue attachment and bone and increased severity of gum disease in certain patients.

Interleukin's test can be used in dental offices and is available in all U.S. states including New York, which monitors the accuracy and reliability of results of laboratory tests and sets one of the highest accreditation standards in the country for genetic testing companies. The company hopes the study results establish reimbursement coverage for the test. The insurance company would not have access to any genetic information, Giannobile said. The information would allow the dentist to make a more informed treatment protocol.

An estimated 75 percent of American adults have some form of gum disease, and roughly 20-25 percent have moderate to severe cases which can lead to tooth loss. The year-long study begins in the fall.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan
Source:Eurekalert

Related biology news :

1. Landmark study unlocks stem cell, DNA secrets to speed therapies
2. Landmark national study reveals significance of green practices in attractions industry
3. 150 years of Darwins landmark book spawns international conference
4. ACLU -- Myriad Genetics lawsuit will become landmark case
5. Landmark project to map genomics of complex ant systems
6. Carnegie donates landmark clones to biology
7. Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product
8. Moa get fewer: Landmark study
9. Lower your blood pressure, hydrate your skin and reduce dental plaque -- with chocolate?
10. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
11. New generation of orthopedic, dental and cardiovascular prostheses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... ... March 30, 2017 , ... DrugDev ... Technology Leadership Council’s NewCo festival on April 5. NewCo invites participants to the ... the inside. , DrugDev – operating at the intersection of innovative healthcare ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... comprising multiple separable adhesive layers, as issued by the U.S. Patent & Trademark ... it applies to combining electronics and health monitoring. This invention will be critical ...
(Date:3/29/2017)... March 29, 2017 QIAGEN N.V. (NASDAQ: QGEN ... the U.S. launch of its ipsogen ® JAK2 RGQ PCR ... and Drug Administration as a qualitative in vitro diagnostic test for the detection ... ... processed on QIAGEN,s Rotor-Gene ® Q MDx system, which is a member ...
(Date:3/29/2017)... and PETACH TIKVAH, Israel ... Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ... neurodegenerative diseases, announced financial results for the ... "2016 was a highly successful and pivotal ... and significant progress made on clinical, regulatory ...
Breaking Biology Technology: